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Gastric cancer often carries a poor prognosis, with an estimated 740,000 deaths from the malignancy occurring yearly worldwide
(Dickenetal.,2005).Themortalityofdiseaseislargelydependentontheextentoftumorspread,asgastriccancerhasapredilection
to metastasize to other visceral secondaries via hematogenous and lymphatic dissemination. Direct invasion of a gastric adenocar-
cinoma to adjacent organs secondary to gastric wall perforation does occur; however, it is often present in the setting of advanced
disease. Rarely does direct tumor invasion to adjacent organs from a gastric adenocarcinoma present as the initial manifestation of
extranodal tumor spread. We present a case of a 40-year-old male with direct tumor extension to the liver as an initial presentation
ofextranodaltumorspreadfromagastricadenocarcinoma.Cliniciansshouldbeawareofsuchanoccurrence,astreatmentmodal-
itiesindirectliverextensionfromagastricadenocarcinomavaryandmaybedirectedtowardspalliationratherthancurativeintent.
1.Introduction
Gastric cancer is the second most common malignancy
worldwide [1]. Although less prevalent in North America;
gastric cancer still accounts for nearly 10, 500 deaths per year
[1]. The median survival time after diagnosis is directly pro-
portional to the extent of extranodal tumor spread. Direct
invasion of a gastric adenocarcinoma to adjacent organs via
perforation of the gastric wall is infrequent and occurs in
the setting of widely disseminated disease [2]. Direct tumor
extension to the liver at initial presentation of a gastric
adenocarcinoma is rare and harbors an extremely poor pro-
gnosis [2, 3]. We present a case of a 40-year old male with
direct tumor extension to the liver as an initial presentation
of extranodal tumor spread from a gastric adenocarcinoma.
2. Case Presentation
A 40-year-old Polish male with no signiﬁcant medical
history presented to the emergency room with complaints of
dysphagia and weight loss for nearly 3 months. The patient
began noticing diﬃculty in swallowing liquids, eventually
progressing to dysphagia for both liquids and solids over the
last several weeks. He described the dysphagia as diﬃculty
passingafoodbolusthroughhisloweresophagusanddenied
anydiﬃcultyinitiatingaswallow.Thepatientalsonoticedan
unintentional weight loss of nearly 30 pounds over the past 3
months. He denied any nausea, vomiting, abdominal pain,
melena, hematemesis, fevers, or chills. The patient denied
the use of any medications, illicit drugs, alcohol, or tobacco.
Family history was noncontributory, including the absence
of any malignancy, gastrointestinal, or neurologic disorders.
Physical examination was remarkable for pallor and
mild midepigastric tenderness without guarding or rigidity.
Digital rectal examination did not reveal any mass lesions
or evidence of gross bleeding. Laboratory evaluation was
signiﬁcant for hemoglobin of 8.9gm/dL with hematocrit
of 27%. Liver transaminases were within normal range;
however, there was an increased alkaline phosphatase noted
to be 205U/L.
The patient was admitted to the medical ward where he
underwent an esophagogastroduodenoscopy (EGD). EGD2 Case Reports in Medicine
Figure 1: A large, fungating gastric cardia mass (arrow) suspicious
for neoplasm seen on esophagogastroduodenoscopy (EGD).
revealed a large, ulcerated, fungating gastric cardia mass
with overlying exudates suspicious for neoplasm (Figure 1).
Severalbiopsieswereobtainedwhichconﬁrmedthepresence
of a moderately diﬀerentiated gastric adenocarcinoma
(Figure 2). Computed tomography (CT) of the head, thorax,
abdomen, and pelvis was remarkable for a 9.15cm ×
7.96cm soft tissue mass within the cardia of the stomach
involving the gastroesophageal junction and along the lesser
curvature.Alsonotedwasextensionofthemassintotheliver
parenchyma suggestive of local tumor invasion (Figure 3).
There was no evidence of invasion to any other organs or
distant metastases.
Given the size and extension of the gastric mass, the
patientwasdeemedapoorsurgicalcandidate.Afteranonco-
logy evaluation, patient underwent chemoradiation therapy
with paclitaxel and carboplatin. The patient was discharged
andcontinuedtofollowwiththeoncologyserviceforfurther
chemoradiation therapy.
The patient returned to the medical emergency room 2
months later after the abrupt onset of large volume hema-
temesis. Emergent EGD revealed the invading gastric mass
was unchanged from previous endoscopic evaluation 2
months prior. Also observed was the presence of blood clots
inthefundus,withnoevidenceofactivebleeding.RepeatCT
of the abdomen was suggestive of increasing tumor invasion
into the liver parenchyma compared to previous imag-
ing done prior to chemoradiation therapy. The patient
refused further diagnostic and therapeutic measures. His
hospitalizationwascomplicatedbyrepeatedmassivehemate-
mesisandmultipleorganfailureleadingtohiseventualdeath
on hospital day 6.
3. Discussion
Gastric cancer is the second most common cancer world-
wide, with the incidence varying with geographical location
[1].Gastriccancerisalsocurrentlythesecondmostcommon
type of cancer-related deaths worldwide with the highest
incidence in Japan, EasternAsia,South America, andEastern
Europe, respectively [1]. In North America, gastric cancer
is relatively infrequent, yet signiﬁcantly contributes to the
Figure 2: Histopathology of the large gastric mass. Note the
irregular gland formation (arrows) highly suggestive of a diﬀuse-
type gastric adenocarcinoma.
Figure 3: A 9.15cm × 7.96cm soft tissue mass within the cardia of
the stomach involving the gastroesophageal junction and along the
lesser curvature. Note the localized invasion of the tumor into the
liver parenchyma.
burdenofcancer-relateddeaths[2–5].In2010,theAmerican
Cancer Society (ACS) reported approximately 21,000 new
cases of gastric cancer, with an estimated 10,500 mortalities.
As with most malignancies, the severity of disease depends
on the stage in which the tumor is ﬁrst discovered along with
the presence of extranodal tumor spread [2].
The most common sites of visceral secondaries from a
primary gastric adenocarcinoma include the lung and liver
with metastases to the brain and bony structures occurring
less frequently [1] .T u m o rs p r e a dt os u c ho r g a n sm o s to f t e n
involves hematogenous spread and dissemination via the
lymphatic system [1–3]. Direct extension of a gastric ade-
nocarcinoma into adjacent structures including the omenta,
diaphragm, transverse colon, and duodenum has been
reported;however,usuallyoccuritisinthesettingofadvanc-
ed disease and the presence of other visceral secondaries
[3]. Direct tumor extension into liver parenchyma from a
gastric adenocarcinoma is infrequent and is rarely the initial
manifestation of extra nodal tumor spread [2, 3].
The classiﬁcation of gastric adenocarcinoma has proven
to be essential in the evaluation of prognoses in patients
with this malignancy. According to the Lauren classiﬁcation,
gastric adenocarcinomas may be diﬀerentiated into two sub-
groups; intestinal type and diﬀuse type [6]. GastricCase Reports in Medicine 3
adenocarcinoma of diﬀu s et y p eh a su n o r g a n i z e dt u m o rc e l l s
diﬀusely inﬁltrating the stroma of the stomach. These tumor
cells often demonstrate deep inﬁltration of the stomach wall
with modest gland formation as seen in our patient. If inﬁl-
tration of the serosal layer by tumor cells occurs, this may
lead to invasion of the tumor to adjacent organs [2, 3].
Direct tumor invasion to liver parenchyma from a gastric
adenocarcinoma is infrequent and occurs in the setting of
advanced disease [2, 3]. In a study by Korenaga et al.,
207 patients with direct tumor invasion to adjacent organs
secondarytoagastricadenocarcinomawerereviewed.Direct
invasion to the liver was found to occur in less than 7 percent
of patients with invasion to the pancreas, mesocolon, and
peritoneum occurring more frequently [3]. Of the patients
noted to have direct extension to the liver, all had evidence of
extra nodal tumor spread. Although direct tumor invasion
to the liver from a gastric adenocarcinoma often heralds
advanced disease, a multitude of therapeutic options have
been considered in this patient population.
Surgical interventions have been attempted in patients
with gastric adenocarcinoma with direct liver invasion. In
a study by Kunisaki et al., 10 patients with direct liver
invasion from a gastric adenocarcinoma were evaluated with
3 patients undergoing curative combined resection of the
gastric and liver tumor. Of these 3 patients, median survival
timewasonly13monthsaftertheprocedurewiththemedian
survival time without curative surgical intervention being
11 months [7]. The therapeutic beneﬁt of curative surgery
may yield low median survival time postoperatively, as it is
extremely diﬃcult to resect the invading tumor completely
[7]. Given the potentially fatal intraoperative risks and
postoperative morbidities associated with curative resection,
clinicians should be cognizant of the minimal prolongation
of median survival time after this procedure.
Chemotherapeutic options are available to patients with
gastric adenocarcinoma and direct invasion to adjacent
organs; however, results are not promising. Randomized
trials on combined chemotherapy agents, such as, cisplatin
along with bleomycin or etoposide have demonstrated statis-
tically signiﬁcant improved survival rates over single chem-
otherapy agents [8, 9]. Clinically combined therapy however,
has shown to only prolong median survival time survival
1 month [8–10]. Newer trials appear to favor a three-drug
combination with a constant infusion of ﬂuorouracil with
cisplatinandananthracycline;however,themortalitybeneﬁt
of this regimen appears unclear [10].
Although surgical intervention and chemotherapeutic
options appear to have only a nominal beneﬁt on median
survival times, they often aid in palliation of symptoms.
Noncurative surgical resection may alleviate symptoms of
abdominal pain, dysphagia, nausea, and vomiting. Palliative
chemotherapy can result in tumor shrinkage, control of neo-
plastic proliferation and altering tumor biology and meta-
bolic activity; thus systemic and local symptom alleviation
may be achieved [11, 12]. Given the high mortality of gas-
tric adenocarcinoma with direct liver extension despite
potentiallycurativeinterventions,palliativemeasuresmaybe
considered as initial therapy in patients with this aggressive
tumor spread.
4. Conclusion
Patients with a gastric adenocarcinoma and direct tumor
extensiontotheliverhaveadismalprognosiswith5-yearsur-
vival rates thought to be less than 15 percent [2, 3]. Although
direct extension to the liver from a gastric adenocarcinoma
often occurs in the setting of advanced extranodal tumor
spread, clinicians should be aware that such a presentation
may occur at initial diagnosis of a gastric adenocarcinoma.
Preliminary treatment options in such patients should be
directed towards palliation, rather than curative intent, as
consequences of such tumor extension prove to be almost
universally fatal.
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